HOME › NEWS
October 22, 2026

rVirogen Wins First Prize at the Pitch Session of the 23rd DIA Japan Annual Meeting 2026

rVirogen, Inc. is pleased to announce that it received First Prize at the Pitch Session of the 23rd DIA Japan Annual Meeting 2026, held on October 19, 2026, at Tokyo Big Sight, Japan.
The session was DIA Japan's first Whale Tank-style pitch event, featuring four Japan-based startups in the healthcare and life sciences sectors. The participating companies presented their business strategies to decision-makers from pharmaceutical companies, regulatory authorities, clinical key opinion leaders (KOLs), corporate venture capital (CVC) firms, and venture capital (VC) firms, with a focus on commercialization and global expansion.
Representing rVirogen, President and CEO Yumesaku Ishigaki presented the company's development program for Panectin®, a Nectin-4-targeted oncolytic virus therapy for non-muscle-invasive bladder cancer (NMIBC), particularly for patients with BCG-unresponsive disease. The judges recognized the clarity of the company's development direction and business strategy, as well as its appropriate consideration of key issues.
As the First Prize winner, rVirogen is eligible to be recommended for a seeded participation opportunity at the DIA Global Annual Meeting.
We will build on the recognition and valuable feedback received at this event to advance the development and commercialization of Panectin®, with the aim of bringing this innovative therapy to patients as soon as possible. We sincerely thank the judges, organizers, and everyone who supported us at the event.

Message from the President and CEO
We are truly honored to receive First Prize at this event. Encouraged by this recognition and the valuable feedback we received, we remain committed to steadily advancing the development of Panectin® and bringing new treatment possibilities to patients in need.
Yumesaku Ishigaki
President and CEO, rVirogen, Inc.